Selux's Next-Generation Phenotyping (NGP) platform provides rapid, high-throughput, fully automated AST results, enabling same-shift susceptibility testing of up to 50 antibiotics in parallel. The platform is driven by Selux's proprietary technologies, which differentiate antibiotic-induced bacterial growth modes through the interplay of novel biochemical assays and cutting-edge artificial intelligence.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/28/22 | $50,000,000 | Series C |
Northpond Ventures RA Capital Management  Sands Capital Schooner Capital | undisclosed |
